ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ibrx · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$15.00
Consensus
$13.00
+83.9% upside
Low
$12.00
Median: $12 · Last Close: $7.07
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$13.00
83.9% upside
High Target
$15
112.2%
Low Target
$12
69.7%
Current Price
$7.07
as of today
Based on analyst price targets, the IBRX stock price prediction for the next 12 months ranges from $12 to $15. The consensus IBRX price forecast of $13.00 implies 83.9% upside from the current price of $7.07.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $6.74 | ↓ 4.63% |
1-day model range: $6.69–$6.8. Peak: $6.8 (-4.63%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IBRX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-21 | BTIG | Maintains | Buy→Buy |
| 2026-05-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-05 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-04-21 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-04-08 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-26 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-23 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-17 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-09 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on ImmunityBio, Inc. (IBRX) stock. Of the recent 68 rating actions, 1 were upgrades and 1 were downgrades. 5 analysts currently cover IBRX.
Analyst Recommendation Trends
IBRX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 7 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$210M
↓ 81.3% YoY
Revenue Next Year
$452M
↑ 115.6% YoY
EPS This Year
$-0.69
EPS Next Year
$-0.10
↓ 84.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast IBRX EPS of $-0.69 for the current fiscal year, based on estimates from 2 analysts. The IBRX revenue forecast is $210M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IBRX stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IBRX price target is $13.00 (+83.9% upside), with an analyst consensus of Buy.
The IBRX short-term stock prediction for tomorrow is $6.74 (-4.63%).
ImmunityBio, Inc. trades on NASDAQ under the ticker IBRX. The IBRX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
IBRX forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month IBRX price target is $13.00, with a high forecast of $15.00 and a low of $12.00. The median price target is shown in the chart above when available. This implies +83.9% potential upside from the current price of $7.07.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.